CHRS
Coherus Oncology·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 3
Consensus Rating "Strong Buy"
High Gross Profit Margin
Significant Net Income Decline
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CHRS
Coherus Oncology, Inc.
A commercial stage biopharmaceutical company that builds a leading immuno-oncology franchise
333 Twin Dolphin Drive, Suite 600, Redwood City, California 94065
--
Coherus Oncology, Inc., was incorporated in Delaware in September 2010. The Company is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative cancer treatments and the commercialization of approved biosimilar combinations. The company's strategy is to build a leading immuno-oncology franchise, funded by cash generated through net sales of a diverse portfolio of U.S. Food and Drug Administration-approved therapies.
Company Financials
EPS
CHRS has released its 2025 Q3 earnings. EPS was reported at -0.33, versus the expected -0.29, missing expectations. The chart below visualizes how CHRS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CHRS has released its 2025 Q3 earnings report, with revenue of 11.57M, reflecting a YoY change of 91.19%, and net profit of -35.53M, showing a YoY change of -230.49%. The Sankey diagram below clearly presents CHRS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
